>AGN – Do you think [Latisse] will ever move to OTC?<
Have dual products would presumably maximize AGN’s profits. Hence, AGN may eventually try to do what Pharmacia & Upjohn did with Rogaine: move the original strength to OTC while introducing a higher-strength Rx version.
One argument for having an Rx version is to get a baseline read on IOP, although I doubt that many prescribing docs will actually do this.
Market Data 
Markets 
AI
